DaVita has launched an expanded value-based care agreement with Humana Medicare Advantage, focusing on earlier intervention for chronic kidney disease (CKD) stages 3B-5. This partnership aims to improve patient outcomes, reduce hospitalizations, and enhance care coordination for over 10,000 patients, building on their existing collaboration in end-stage kidney disease.
DaVita (DVA) has announced an expansion of its value-based care partnership with Humana (HUM) to address chronic kidney disease (CKD) stages 3B-5 for over 10,000 Medicare Advantage members. This is significant because it moves DaVita's intervention earlier in the disease progression, where it can have a greater impact on patient outcomes and potentially reduce the need for more costly end-stage kidney disease treatments. For DaVita, this represents a growth opportunity in value-based care and strengthens its position as a leader in integrated kidney care. For Humana, it enhances its Medicare Advantage offerings, potentially leading to better health outcomes for its members and long-term cost savings. In the short term, this is a positive development for both companies, signaling continued collaboration and a focus on preventive care. Long-term, successful implementation could solidify their market positions in value-based healthcare, though execution risk always remains.